Status:

COMPLETED

Comparison of Safety and Efficacy of Intravenous Iron Versus Oral Iron in Chronic Renal Failure Subjects With Anemia

Lead Sponsor:

American Regent, Inc.

Conditions:

Anemia

Eligibility:

All Genders

18+ years

Phase:

PHASE3

Brief Summary

To assess the safety and efficacy of two forms of iron therapy for the treatment of anemia in non-dialysis dependent, chronic renal failure in patients receiving or not receiving erythropoietin.

Detailed Description

The intent of this study was to assess the safety and efficacy of two forms of iron therapy for the treatment of anemia in non-dialysis dependent, chronic renal failure patients receiving or not recei...

Eligibility Criteria

Inclusion

  • Hemoglobin \< or = 11.5 gm/dL
  • Stable dose or not receiving EPO
  • Renal Anemia

Exclusion

  • IV iron with last 6 months
  • Chronic infection, malignancy,major surgery within last month
  • Blood Transfusion with last two months
  • Significant blood loss within last 3 months
  • Concomitant sever diseases of the liver

Key Trial Info

Start Date :

August 1 2003

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

October 1 2004

Estimated Enrollment :

182 Patients enrolled

Trial Details

Trial ID

NCT00236977

Start Date

August 1 2003

End Date

October 1 2004

Last Update

October 6 2020

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Luitpold Pharmaceuticals

Valley Forge, Pennsylvania, United States, 19403